A randomized, placebo-controlled Phase 2 trial (NCT02453711) of once-daily subcutaneous semaglutide (0.05, 0.1, 0.2, 0.3, or 0.4 mg following 4-weekly escalations) in subjects with obesity without T2D, showed mean weight losses of -6.0% (0.05 mg) to -13.8% (0.4 mg) with semaglutide vs -2.3% with placebo at week 52
This means retatrutide may offer additional benefits and improve outcomes , although more evidence is needed as clinical trials continue
Beyond its quantitative efficacy, retatrutides ability to improve hepatic steatosis, glycemic control, and inflammatory markers suggests that next-generation triple agonists may provide surgery-comparable, yet less invasive, pathways to durable metabolic restoration
Whether youre a professional athlete, a fitness enthusiast, or someone looking to optimize physical performance, maintaining adequate levels of glutathione for athletes can make a substantial difference in your training and recovery